CAL
SGMO

Capital Advisors Ltd’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Capital Advisors Ltd’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-128
Closed – – 1617
2024
Q1 		$0 Buy
+128
New +$93 ﹤0.01% 1529
2022
Q4 		– Sell
-93
Closed – – 1592
2022
Q3 		$0 Hold
93
– – ﹤0.01% 1484
2022
Q2 		$0 Buy
+93
New +$402 ﹤0.01% 1292

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital Advisors Ltd's SGMO Position: Q2 2024 in Review

Capital Advisors Ltd sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2024, closing a stake of 128 shares.

Capital Advisors Ltd first reported a position in SGMO in Q2 2022 and held it in 3 quarters. The position peaked at $0 in Q1 2024. 129 funds tracked by Wall St. Rank hold SGMO as of Q2 2024.

  • Capital Advisors Ltd reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2024 after selling out during the quarter.
  • Capital Advisors Ltd sold 128 SANGAMO THERAPEUTICS INC shares in Q2 2024.
  • Capital Advisors Ltd first reported a position in SANGAMO THERAPEUTICS INC in Q2 2022 and held it in 3 quarters.
  • Capital Advisors Ltd's SANGAMO THERAPEUTICS INC position peaked at $0 in Q1 2024.
  • 129 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2024.

Based on Capital Advisors Ltd's 13F filing for Q2 2024, filed 25 Jul 2024.